title: Glycoprotein Ib-IX-mediated activation of integrin alpha(IIb)beta(3): effects of receptor clustering and von Willebrand factor adhesion.
abstract: The interaction between the platelet glycoprotein (GP) Ib-IX complex and von Willebrand factor (VWF) initiates both hemostasis and pathological thrombosis. This interaction is not only the first adhesive event of platelets at sites of vessel injury, but also facilitates fibrinogen binding to alpha(IIb)beta(3), which subsequently results in platelet aggregation. Since it has been suggested that GP Ib-IX clustering may promote platelet activation, we investigated the effect of such clustering on both VWF-GP Ib-IX and fibrinogen-alpha(IIb)beta(3) bonds using optical tweezers. In our system, fusion of tandem repeats of FK506-binding protein (FKBP) to the cytoplasmic tail of the GP IX subunit of the GP Ib-IX complex allowed subsequent receptor clustering within the plasma membrane by the bivalent, cell-permeant small molecule ligand AP20187. We measured binding forces between polystyrene beads coated with either plasma-derived VWF or the VWF A1 domain and GP Ib-IX(FKBP)2, and those between fibrinogen-coated beads and alpha(IIb)beta(3) expressed on Chinese hamster ovary cells. The minimal detachment force between GP Ib-IX(FKBP)(2) and A1 or plasma-derived VWF doubled after AP20187 was added. The binding force between immobilized fibrinogen and alpha(IIb)beta(3) was not changed by the clustering agent; however, the strength of single fibrinogen-alpha(IIb)beta(3) bonds increased significantly after ligation of GP Ib-IX(FKBP)(2) by A1. These results demonstrate that GP Ib-IX clustering increases the overall strength of its interaction with VWF. Furthermore, signals from GP Ib-IX can activate alpha(IIb)beta(3), thereby increasing the strength of its interaction with fibrinogen.
authors.affiliation: Department of Bioengineering, Rice University, Houston, TX 77251, USA.
authors.forename: M
authors.initials: M
authors.lastname: Arya
authors.forename: J A
authors.initials: JA
authors.lastname: López
authors.forename: G M
authors.initials: GM
authors.lastname: Romo
authors.forename: M A
authors.initials: MA
authors.lastname: Cruz
authors.forename: A
authors.initials: A
authors.lastname: Kasirer-Friede
authors.forename: S J
authors.initials: SJ
authors.lastname: Shattil
authors.forename: B
authors.initials: B
authors.lastname: Anvari
mesh_terms: D000268:Adhesiveness; D000818:Animals; D016466:CHO Cells; D002448:Cell Adhesion; D006224:Cricetinae; D005340:Fibrinogen; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics / Q000378:metabolism*; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D010980:Platelet Membrane Glycoproteins; D011485:Protein Binding; D011940:Receptor Aggregation; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D014162:Transfection; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: C463061:AP20187; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; D010980:Platelet Membrane Glycoproteins; C032193:glycoprotein receptor GPIb-IX; D014841:von Willebrand Factor; D005340:Fibrinogen; D016559:Tacrolimus